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Abstract: 
Bisphenol-A is an endocrine disrupting compound widely used in the 
production of polycarbonate plastics and epoxy resins. It is ubiquitously 
present in the environment, mostly in aquatic environments, with 
consequent risks to the health of aquatic organisms and humans. In the 
present study we analysed the cytogenetic effects of bisphenol-A on human 
lymphocytes using in vitro chromosomal aberrations and micronuclei 
assays. Lymphocyte cultures were exposed to five different concentrations 
of BP-A (0.20, 0.10, 0.05, 0.02 and 0.01 µg/mL) for 24 h (for 
chromosomal aberrations test) and 48 h (for micronuclei test). The 
concentration of 0.05 µg/mL represents the reference dose established by 
United States Environmental Protection Agency; 0.02 µg/mL represents the 
higher concentration of unconjugated BP-A found in human serum and 
0.01 µg/mL represents the tolerable daily intake established by European 
Union. Data obtained with both assays showed significant genotoxic effects 
of the bisphenol-A at concentrations of 0.20, 0.10 and 0.05 µg/mL, 
whereas at the concentration of 0.02 µg/mL we observed only a significant 
increase in the micronuclei frequency. Finally, at the concentration of 0.01 
µg/mL no cytogenetic effects were observed, indicating this latter as a 
more tolerable concentration for human health with respect to 0.05 µg/mL, 
the reference dose established by US EPA. 
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Summary 
Bisphenol-A is an endocrine disrupting compound widely used in the production of polycarbonate 
plastics and epoxy resins. It is ubiquitously present in the environment, mostly in aquatic 
environments, with consequent risks to the health of aquatic organisms and humans. In the present 
study we analysed the cytogenetic effects of bisphenol-A on human lymphocytes using in vitro 
chromosomal aberrations and micronuclei assays. Lymphocyte cultures were exposed to five 
different concentrations of BP-A (0.20, 0.10, 0.05, 0.02 and 0.01 µg/mL) for 24 h (for chromosomal 
aberrations test) and 48 h (for micronuclei test). The concentration of 0.05 µg/mL represents the 
reference dose established by United States Environmental Protection Agency; 0.02 µg/mL 
represents the higher concentration of unconjugated BP-A found in human serum and 0.01 µg/mL 
represents the tolerable daily intake established by European Union. Data obtained with both assays 
showed significant genotoxic effects of the bisphenol-A at concentrations of 0.20, 0.10 and 0.05 
µg/mL, whereas at the concentration of 0.02 µg/mL we observed only a significant increase in the 
micronuclei frequency. Finally, at the concentration of 0.01 µg/mL no cytogenetic effects were 
observed, indicating this latter as a more tolerable concentration for human health with respect to 
0.05 µg/mL, the reference dose established by US EPA. 
Keywords:  
BP-A, endocrine disruptors, micronucleus assay, chromosomal aberrations assay, human 
lymphocytes.  
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1. Introduction 
 
In the last decades, global production of plastic has continued to rise. Recovery and recycling, 
however, remain insufficient and millions of tons of plastic compounds continue to accumulate in 
the environment. Most of these compounds have adverse effects on the biome and pose huge risks 
for the human health. Some of them are reported to be endocrine disrupting compounds (EDCs), 
mimicking or blocking natural hormone action and altering the normal functioning of the endocrine 
system of invertebrate and mammals species.1 
Among EDCs, bisphenol A (BP-A: 4,4'-(propane-2,2-diyl)diphenol) has received much attention 
due to its high production volume and widespread human exposur. 2 BP-A is an important synthetic 
compound used in the production of polycarbonate plastics and as a precursor of epoxy resins. A 
wide range of consumer products contain BP-A, including water and baby bottles, food packaging 
materials, internal coatings of cans and drums, toys, water pipes, sports equipment, medical and 
dental devices, and household electronics.3  
Due to the daily use, BP-A was found in all environmental matrices such as air, water, soil, 
sediment, and sewage sludge. It is released into the environment either through sewage treatment 
effluent, landfill leachate, untreated urban and industrial wastewater or natural degradation of 
polycarbonate plastics.4 For these reasons, BP-A was found at relatively high concentrations (up to 
hundreds of µg/L) in several rivers and lakes worldwide.5 
Being BP-A used for food packaging, bottles, and coatings for tins, human exposure to this 
compound is extremely variable depending on life-styles, principally dietary consumption habits. 
 In general, humans are chronically exposed to low doses of the compound, mainly through food 
and drinking water. 6 However, the release of BP-A from polycarbonates is accelerated by UV light, 
aging, heating, or following pH changes due to the contact with acidic or basic compounds.7 It has 
been shown that upon long-term heating BP-A can leach from plastic baby bottles into an aqueous 
solution.8 For these reasons, firstly in Canada, Denmark and next in all European countries, BP-A 
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has been banned in infant formula bottles.9  
Neverthless, many plastic food and drinking containers still contain BP-A and its presence has been 
reported in human serum and in 95% of the urine samples obtained from a reference population in 
the United States,10 as well as in maternal and fetal plasma,11 placental tissue,12 and in the milk of 
lactating mothers.13 Several studies, using different analytical techniques, have also measured the 
unconjugated BPA concentrations in human serum, reporting values ranging from 0.2 to 
20 ng/mL.2 Finally, the estimated exposure of the general population to BP-A is supposed to reach 
a body burden of up to 9 µg/kg/day.14  
In humans, BP-A is rapidly absorbed from the gastrointestinal tract and conjugated with glucuronic 
acid in the liver. The formed glucuronide is then cleared from blood by elimination with urine 
within 24 h after oral administration. This rapid excretion results in a low body burden of the BP-A 
in humans following oral absorption of low doses.15 However, despite its rapid rate of excretion, as 
consequence of its ubiquitous and widespread distribution, BP-A has arisen worldwide concerns 
about its possible associations with human diseases such as obesity 6 and cancer.16 At reproductive 
system level, exposure to ECDs seems to be associated with decreased fertility and increased risk of 
testicular or prostate cancer in men,17 whereas in women exposure to ECDs seems to increase the 
risk of endometriosis, reproductive or other endocrine-related cancers.18 
From the genetic point of view, the genotoxicity of BP-A has been evaluated in several in vitro and 
in vivo studies, although with controversial results. BP-A was found to be able to induce increase of 
chromosome aberrations (CAs) and DNA adducts in Syrian hamster embryo cells,19 micronuclei 
(MNs) in human MCL-5 cells 20 and in fish erythrocytes, 21 MNs and CAs formation in CHO 
cells.22 A significant genotoxic effect by BP-A was also seen on bovine peripheral lymphocytes in 
vitro, but only at the highest concentration of 1x10-4 M. 23 Moreover, Tiwari et al. 24 observed a 
significant increase of MNs in polychromatic erythrocytes, structural CAs in bone marrow cells and 
DNA damage in lymphocytes of rats exposed to BP-A. Interestingly, in HEK293 cells, BP-A was 
found to alter the expression of some genes involved in important biological processes including 
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ion transport, cysteine and glycogen metabolic processes, apoptosis, DNA damage repair and many 
others 25. 
On the other hand, BP-A failed to induce gene mutations in Syrian hamster cells, 19 polyploidy or 
MNs in male mice, 26 and sister chromatid exchanges in mouse lymphoma cells.27  
Nevertheless, based on published data, the United States Environmental Protection Agency (US 
EPA) has set a reference dose (RD) for BP-A oral exposure of 0.05 mg/kg body weight 
(BW)/day.28 More recently, the European Union (EU) 14 established a temporary tolerable daily 
intake (TDI) for BPA of 10 µg/kg BW/day, based on a consideration of much toxicological data, 
including the effects of BPA on reproductive organs and functions, and hormonal effects in 
animals.  
No data are reported in literature about in vitro cytogenetic effects of BP-A on human lymphocytes.  
For this reason, in the present study we assessed the possible in vitro clastogenic and aneugenic 
effects of BP-A exposure on human lymphocyte cells, by CAs and MNs assays.  
It has been shown that a high frequency of the chromosomal damage is a predictive value of health 
risk. 29 In this scenario, CAs and MNs assays are important tools in the measurement of the 
genotoxic potential of many chemicals, including BP-A. The CAs assay allows the detection of 
cells carrying unstable aberrations (chromosome and chromatid breaks, deletions, fragments, rings, 
dicentrics and chromatid exchanges) that will lead to cell death during proliferation.30 Previous 
studies have provided strong evidence in support of the hypothesis that high CAs frequency in 
peripheral blood lymphocytes is a powerful predictor of cancer risk. Indeed, it is known that cancer 
incidence among healthy individuals of a population increases with increased levels of CAs in their 
circulating lymphocytes.29 On the other hand, MNs are used as a fast and reliable assay for 
detecting both potential clastogenic (chromosome breakage) or aneugenic (chromosome lagging 
due to dysfunction of mitotic apparatus) effects of different xenobiotics. In particular, MNs 
represent acentric chromosomal fragments or whole chromosomes left behind during mitotic cell 
division and appear in the cytoplasm of interphase cells as small additional nuclei.  Bonassi et al. 31 
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provided evidences that also increased MNs frequencies in peripheral blood lymphocytes are 
positively associated with early events in carcinogenesis.  
In the present study, we tested concentrations of 0.20, 0.10, 0.05, 0.02 and 0.01 µg/mL, where 0.05 
µg/mL represents the RD established by US EPA; 28 0.20 µg/mL and 0.10 µg/mL are multiples of 
this RD in order to establish a possible dose-dependent increase of the genomic damage; 0.020 
µg/mL represents the higher concentration of unconjugated BP-A found in literature in human 
serum, 2 and 0.01 µg/mL is the TDI established by EU. 14  
 
 
2. Methods 
 
2.1 Chemicals and Media 
The IUPAC name of Bisphenol-A (BP-A, CAS n. 80-05-7) is: 4,4'-(propane-2,2-diyl)diphenol. The 
BP-A was dissolved in Dimethyl Sulfoxid  (DMSO, CAS no. 67-68-5). Gibco RPMI 1640 cell 
culture media supplemented with L-glutamine, foetal calf serum, phytohemagglutinin (PHA), and 
antibiotics were purchased from Invitrogen-Life Technologies, Milan, Italy. Cytochalasin-B, 
Mitomycin-C (MMC), BP-A and Giemsa stain solution were obtained from Sigma-Aldrich, Milan, 
Italy. Methanol, Acetic acid, and conventional microscope slides were purchased from Carlo Erba 
Reagenti, Milan, Italy. Potassium chloride (KCl) and Sörensen buffer were obtained from Merck 
S.p.A., Milan, Italy. Vacutainer blood collection tubes were from Terumo Europe, Rome, Italy.  
 
2.2 Subjects 
Peripheral venous blood was collected from 5 healthy female subjects (mean age±S.D., 27.60±5.22, 
range 22-30 years), non-smoking, non-alcoholic, not under drug therapy, and with no recent history 
of exposure to mutagens. Informed consent was obtained from all blood donors. The study was 
approved by the Univeristy of Turin ethics committee and was performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki.  
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2.3 Blood Sample Collection and Lymphocyte cultures 
Heparinized blood samples were obtained by venipuncture and collected in heparinised tubes, for 
genotoxicity testing. All blood samples were coded, cooled (4°C), and processed within 2 h after 
collection. Heparinized venous blood (0.3 mL) was cultured in 25 cm2 flasks in 6 mL of RPMI-
1640 medium supplemented with 20% foetal calf serum (FCS), 2% of the mitogenic agent PHA, L-
glutamine (2 mM), antibiotics (100 IU/mL penicillin, and 100 µg/mL streptomycin). The cultures 
were incubated for 72 h at 37°C, under 5% of CO2 in the air in a humidified atmosphere. After 24 h 
of incubation, BP-A dissolved in DMSO (for stock solution preparation 200 µg of BP-A were 
dissolved in 1 mL of DMSO) was added to the cultures to a final concentrations of 0.20 µg/mL, 
0.10 µg/mL, 0.05 µg/mL, 0.02 and 0.01 µg/mL. The concentration at 0.05 µg/mL represents the RD 
established by US EPA 28 (0.05 mg/kg BW); 0.20 µg/mL and 0.10 µg/mL are multiples of this RD; 
0.020 µg/mL represents the higher concentration of unconjugated BP-A found in literature in 
human serum, 15 and 0.01 µg/mL is the TDI established by EU 14 (10 µg/kg BW). 
Three control cultures were assessed: 1) positive control, by adding only MMC (final concentration 
0.1 µg/mL culture); 2) solvent control, by adding only 0.1% of DMSO; 3) negative control, culture 
without both BP-A and DMSO. Only for MNs assay, after 44 h of incubation, cytochalasin-B was 
added to the cultures at a concentration of 6 µg/mL to block cytokinesis.  
After 48 h (for CAs assay) and 72 h (for MNs assay) of incubation at 37°, the cells were collected 
by centrifugation and treated for 10 min with a pre-warmed mild hypotonic solution (75 mM KCl). 
After centrifugation and removal of the supernatant, the cells were fixed with a fresh mixture of 
methanol/acetic acid (3:1 v/v). The treatment with the fixative was repeated three times. Finally, the 
supernatant was discarded and the pellet, dissolved in a minimal volume of fixative, was seeded on 
the slides to detect CAs and MNs by conventional staining with 5% Giemsa (pH 6.8) prepared in 
Sörensen buffer. 
 
2.4 Cytokinesis-Block Micronucleus Assay  
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Microscope analysis was performed at 40X magnification on a light microscope (Dialux 20, Leica, 
Germany). MNs were scored in 1000 binucleated lymphocytes with well-preserved cytoplasm per 
subject (total 5000 binucleated cells per concentration), following the established criteria for MNs 
evaluation. 32 A total of 1000 lymphocytes per donor per concentration were scored to evaluate the 
percentage of cells with 1-4 nuclei. The cytokinesis-block proliferation index (CBPI) was 
calculated, according to the following formula: [1 × N1] + [2 × N2] + [3 × (N3 + N4)]/N, where 
N1–N4 represents the number of cells with 1-4 nuclei, respectively, and N is the total number of 
cells scored. 
 
2.5 Chromosomal Aberrations Assay  
Microscope analysis was performed at 1000X magnification on a light microscope (Dialux 20, 
Leica, Germany). Althogh the Organization for Economic Co-operation and Development (OECD) 
guidelines call for 300 metaphases to be scored for each dose,33 in order to obtain results more 
significant and suitable for statistical analysis, it is the normal practice in our laboratory to score 
200 metaphases per subject per dose. Thus, in the present work, for each subject and BP-A 
concentration, 200 well-spread first-division complete metaphases (for a total of 1000 metaphases 
for each dose) containing 46±1 chromosomes were analysed for the following categories of CAs: 
gaps, chromatid breaks (B’), chromosome breaks (B”), dicentrics (Dic), rings (R), tri- or tetra-
radials (TR), acentric fragments (AF), rearrangements (Re) and numerical aberrations. Cells 
containing one of more types of CAs were scored as "aberrant cell” (Ab.C).   
With regard to the opportunity to include gaps in the statistical analyses, the discussion is open.  
Although some authors considered gaps as the appropriate indicator of genotoxic potential of 
chemicals, 34 the molecular mechanism of BP-A to induce achromatic lesion/gaps is yet to be 
revealed. Thus, in our statistical analyses we decided to exclude gaps.  
 
2.5 Statistical analysis 
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Comparison of mean values of the percentage of cells with MNs, CBPI and CAs between 
exposition levels and their controls was assessed by the non-parametric Wilcoxon Mann-Whitney U 
test. Statistical calculations were carried out using the SPSS software package program (version 
23.0, Inc., Chicago, IL, USA). All P values were two tailed, and P values of 5% or less were 
considered statistically significant for all tests carried out. 
 
3. Results 
 
3.1 Effect of BP-A on CAs formation 
Table 1 shows values of CAs found in the human peripheral lymphocytes cultured in the presence 
of different concentrations of BP-A. BP-A was found to induce seven types of structural CAs (gaps, 
chromatid and chromosome breaks, dicentric chromosomes, rings, tri- or tetraradials, acentric 
fragments and rearrangements). No numerical aberrations were found. 
Data obtained indicated that human lymphocytes treated in vitro with BP-A at concentrations of 
0.20, 0.10 and 0.05 µg/mL significantly increased the CAs frequency compared with the solvent 
control, whereas at the lower concentrations of 0.02 and 0.01 µg/mL this effect was not observed.  
Among tested concentrations, significant differences were found between 0.02 and 0.01 µg/mL and 
the other three tested concentrations (with p-value of P = 0.001, P = 0.028 and P = 0.023, 
respectively, for 0.02 µg/mL and P < 0.001, P = 0.006 and P = 0.006, respectively, for 0.01 
µg/mL), as well as between the higher tested concentration (0.20 µg/mL) and 0.05 µg/mL (P = 
0.010). As already observed in our previous work, the DMSO solvent-control cultures did not show 
any difference compared to the control cultures (P = 0.058) confirming that, at this low dose 
(0.1%), DMSO has no relevant biological effects. Finally, as expected, control cultures treated with 
the known mutagen MMC showed a significant increase of CAs with respect to all BP-A tested 
concentrations (P < 0.001), as well as to the negative and solvent control cultures (P < 0.001). 
 
3.2 Effect of BP-A on MNs formation 
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To verify both the aneugenic and clastogenic effects of BP-A, the MN test was assessed in parallel 
with CAs test (Table 2). Our results indicated that BP-A significantly, and in a dose-dependent 
manner, increased the MNs formation compared with the negative and solvent controls, at all 
concentrations tested, including 0.02 µg/mL, that represents the higher concentration of 
unconjugated BP-A found in literature in human serum.2 Similarly to what we already observed 
with the CAs assay, at the concentration of 0.01 µg/mL, that represent the TDI established by EU,14 
no significant cytogenetic effects were observed. 
The highest tested concentration (0.20 µg/mL) caused a fourfold increase of MNs as compared with 
the solvent culture. Moreover, significant differences in MNs frequency were also found between 
0.20 µg/mL and all other concentrations, as well as between 0.10 µg/mL and the last two lower 
concentrations (0.02 and 0.01 µg/mL). The solvent-control cultures did not show any difference 
with the negative controls (P = 0.059), further confirming that at this low concentration DMSO has 
no cytogenetic effects. Similarly to what we observed with CAs assay, cultures treated with the 
mutagen MMC showed a substantially increased MNs formation compared with the negative 
control, solvent controls and all tested concentrations of BP-A. Finally, after 48-h exposure, a 
significant reduction of the CBPI value in cultures treated with BP-A was not observed, indicating 
that BP-A does not seem to produce effects on the proliferation/mitotic index when its 
concentration is equal or less than 0.20 µg/mL.  
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4. Discussion 
The genotoxicity of BP-A has been evaluated in several in vitro and in vivo studies, although with 
controversial results.22, 23,24,26 Here, we discuss data obtained from our in vitro study conducted in 
order to establish the clastogenic and aneugenic potential of BP-A on human cultured lymphocytes. 
The results obtained in the present in vitro study with CAs and MNs assays evidenced a possible 
clastogenic effect of the BP-A on human lymphocytes, also at the concentration of 0.05 µg/mL that 
represents the reference dose established for humans by the US EPA.28  This result is consistent 
with that obtained by Tayama et al.,35 who demonstrated that BP-A, in cultured CHO-K1 cells, is 
able to induce significant structural CAs, like gaps, breaks and exchanges. Similarly, Xin et al. 22 
observed a significant increase of MNs frequency in CHO cells after 24 h exposure to doses of 80 
and 120 µM of BP-A (corresponding to 0.018 and 0.027 µg/mL, respectively). Finally, Parry et al. 
20 and Johnson and Parry 36 showed that BP-A cause MNs induction, also in these cases in a dose-
dependent manner, on MCL5 and AHH-1 human lymphoblastoid cell lines and Chinese hamster 
V79 cells.  
The increase of cytogenetic damage observed with both CAs and MNs assays at concentration of 
0.05 µg/mL pushes towards the adoption of lower reference limits. Indeed, increased CAs and MNs 
frequencies in peripheral blood lymphocytes have been positively associated with increased cancer 
risk and early events in carcinogenesis, respectively. 29,31 Vice versa, at the concentration of 0.01 
µg/mL, the TDI established by the EU (2002) 14, no cytogenetic effects were observed, indicating 
that this latter represents a more safe concentration for human health with respect to 0.05 µg/mL.  
The clastogenic properties of the BP-A were attributed by Adamkis et al. 37 to its capacity to 
interact with the cell microtubules causing their depolymerization and consequent manifestation of 
chromosomal abnormalities. Moreover, it is evident from the literature that BP-A is able to generate 
ROS by decreasing the activities of antioxidant enzymes and increasing lipid peroxidation. A 
possible consequence of this action could be the increase of the cellular oxidative stress that is 
considered one of the possible mechanisms underlying DNA damage. 38 BP-A was also found to be 
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able to up-regulate the expression of ERCC5 encoding a DNA endonuclease involved in 
nucleotide-excision repair. This is an important issue because a reduced repair capacity has been 
reported to be associated with increased risk of genomic damage and cancer development. 39  
However, we cannot ascribe the observed cytogenetic damage exclusively to the direct effect of 
BP-A on lymphocytes. Indeed, in vitro studies showed that BP-A is converted to DNA-binding 
metabolites. In particular, BP-A is oxidized to bisphenol-o-quinone whose chemical reaction with 
DNA produces adducts in vitro and in vivo.40 The irreversible binding of BP-A derived compounds 
to DNA could cause bases loss from the DNA strand and could be responsible for some of the BP-
A observed toxic effects. It is known that many chemicals, either directly or after conversion to 
reactive metabolites, covalently modify nucleosides of DNA leading to mutational changes and, 
thus, playing a role in cellular toxicity or tumorigenesis induction.40  
Moreover, it should be also emphasized that the link between observed toxicological effects and 
BP-A exposure, especially at low doses, is complicated by the fact that BP-A is prevalent in many 
consumer products, including common laboratory plastics, and has the potential to leach from these 
products. Consequently, these background concentrations of BP-A have the potential to affect the 
results of in vitro studies that detect low concentration effects.41 Indeed, some in vitro studies 
showed that BP-A induces significant effects also to nominal concentrations. For example, a BP-A 
concentration of 0.23 pg/mL was found to promote proliferation of human seminoma cells (JKT-
1).42  
Interestingly, BP-A increased MNs frequency also at the concentration of 0.02 µg/mL, where CAs 
failed. These apparently discordant results could be explained by the fact that the MNs assays 
reveal alterations in either chromosome number or chromosome structure, whereas the CAs 
analysis can detect alterations only in the chromosome structure. One of the mechanisms of action 
of aneugenic chemicals is the induction of alterations to centromeric DNA, with consequent failure 
of the damaged chromosomes to attach to the mitotic spindle. As also postulated by other authors 
for other xenobiotics 43, it is possible that BP-A may also damage the chromosomes centromeres, 
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determining MNs formation. Moreover, disruption of the mitotic machinery, i.e. microtubules and 
microtubule organizing centers, has been shown to be the mechanism of action for BP-A induced 
spindle-damaging effects. 44  In this scenario it can be hypothesized that BP-A might induce 
aneuploidy through non-disjunction.  
 
5. Conclusion 
In conclusion, the results reported herein demonstrate cytogenetic effects of BP-A on cultured 
human lymphocytes by increasing MNs and CAs frequencies. A large number of studies showing 
the clastogenic and toxic properties of BP-A were performed using different cell models. For these 
reasons, although simple experimental models, like mammalian and bacterial cells, cannot 
accurately mimic the complex kinetics of xenobiotic compounds in vivo, our results suggest the 
adoption of more stringent measures in order to reduce the presence of this compound in the 
environment and to minimize the adverse health effects of BP-A exposure. Finally, being BP-A 
converted in vivo and in vitro in DNA binding metabolites, it would be useful and interesting to test 
in vitro also the genotoxicity of the BP-A metabolites or a combination of both BP-A and its 
metabolites. Indeed, BP-A was found to have a short half-life (47 h in H295R cells) 45 and therefore 
it is conceivable that in in vitro systems about 50% of BP-A could not be metabolized after 48 h 
treatment (typical of MNs assay) and more than 50% after 24 h treatment (typical of CAs assay). In 
this sense, a combined genotoxic action of both BP-A and its metabolites cannot be excluded. 
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Table 1 – Induction of chromosomal aberrations by Bisphenol-A in human lymphocytes in vitro. 
CAs = chromosomal aberrations; Ab.C = aberrant cells (cells with 1 ore more aberrations); NC = Negative Control; MMC = Mitomycin-C; 
BP-A = bisphenol-A; B’: chromatid break; B’’: chromosome break; DC: dicentric; R: ring; TR = tri-tetraradials; AF = acentric fragments;   
Re = rearrangements; S.E. = standard error.  
P < 0.001*, P = 0.001** and P = 0.002 *** with respect to DMSO control; P < 0.001& with respect to all BP-A concentration and DMSO control. 
P < 0.001
$
 with respect to all BP-A concentrations 
Test 
substance 
 
Treatment 
Period      Dose 
  (h)         (µg/ml) 
  
Total 
Scored 
Metaphases 
CAs 
 
Gaps      B’       B’’    DC       R      TR      AF      Re 
Total 
CAs 
Total 
CAs 
+ 
Gaps 
Total 
Ab.C 
Total 
Ab.C 
+ 
Gaps 
CAs/Cell ± S.E. 
(%) 
Ab.C/Cell ± S.E. 
(%) 
NC ---- ---- 1000 2 2 0 1 0 0 1 0 4 6 4 6 0.40±0.10$ 0.40±0.10$ 
0.1% DMSO 24 ---- 1000 8 7 1 1 0 2 1 1 13 21 13 21 1.30±0.30 1.30±0.30 
MMC 24 0.10 1000 38 35 24 11 6 14 26 10 126 164 123 161 12.60±1.30& 12.30±1.00& 
BP-A 24 0.20 1000 17 29 7 10 1 0 18 5 70 87 70 87 7.00±0.70*  7.00±0.70* 
BP-A 24 0.10 1000 16 22 3 5 2 2 8 7 49 65 49 65 4.90±0.60**  4.90±0.60** 
BP-A 24 0.05 1000 8 17 3 5 0 0 11 6 42 50 41 50 4.20±0.90***  4.10±0.90*** 
BP-A 24 0.02 1000 8 6 2 2 2 0 7 6 25 33 25 33 2.50±0.40  2.50±0.40 
BP-A 24 0.01 1000 6 5 2 1 1 0 5 5 19 25 19 25 1.90±0.30 1.90±0.30 
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Table 2 – Induction of micronuclei by Bisphenol-A in human lymphocytes in vitro. 
 
Test 
substance 
Treatment 
Period      Dose 
    (h)       (µg/ml) 
BNCs 
scored 
Distribution of BNCs 
according to the 
number of MN 
 1       2        3        4 
MNs Ab.C 
MN/cell ± S.E. 
(‰) 
 
Ab.C/cell ± S.E. 
(‰) 
CBPI ± S.E 
NC ---- ---- 5000 9 1 0 0 11 11 2.20±0.20$ 2.20±0.20$ 1.712±0.003 
0.1% DMSO 48 ---- 5000 15 1 1 0 20 16 4.00±0.55 3.20±0.37 1.565±0.092 
MMC 48 0.10 5000 102 4 3 2 127 121 25.40±1.21* 24.20±1.20* 1.354±0.019 
BPA 48 0.20 5000 72 2 2 1 86 78 17.20±2.31* 15.60±1.47* 1.584±0.046 
BPA 48 0.10 5000 66 1 0 0 68 65 13.60±1.17* 13.00±1.30*** 1.546±0.017 
BPA 48 0.05 5000 55 0 3 0 64 56 12.80±1.16** 11.20±0.49*** 1.585±0.016 
BPA 48 0.02 5000 46 0 0 0 46 46 9.20±1.63** 9.20±1.63** 1.633±0.005 
BPA 48 0.01 5000 31 0 0 0 31 25 6.20±0.80 5.00±0.95 1.640±0.009 
BNCs = Binucleated cells; MNs = micronuclei; Ab.C = Aberrant cells (cells with 1 or more MNs); NC = Negative Control;  
MMC = Mitomycin-C; BP-A = Bisphenol-A; S.E. = Standard Error. CBPI = Cytokinesis-Block Proliferation Index.  
P = 0.042*, P = 0.043** and P = 0.039*** with respect to DMSO control.  P<0.001$ with respect to all BP-A concentrations and MMC 
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